

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: BOREA ET AL.

Group Art Unit: 1614

Serial No.: 10/603,406

Examiner: Gembah, Shirley V.

Filed: June 24, 2003

Attorney Docket No.: PAT-0040-US-NP2

For: ENHANCING TREATMENT OF MDR CANCER WITH ADENOSINE A₃
ANTAGONISTS

Mail Stop: AF

Conf. No.: 4184

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

AMENDMENT UNDER 37 C.F.R. § 1.116

Sir:

This is in response to the Office communication dated August 28, 2008 in connection with the above identified Application No. 10/603,406, filed June 24, 2003.

Please enter the following:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 5 of this paper.

It is estimated that no fees are required for filing this Amendment. Notwithstanding, if a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to King Pharmaceuticals Deposit Account No. 50-3706.